Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
Rhea-AI Summary
Iterum Therapeutics (Nasdaq: ITRM) will release its third quarter 2025 financial results before U.S. market open on Friday, November 14, 2025.
Management will host a conference call at 8:30 a.m. ET the same day to discuss results and provide a business update. Dial-in numbers are 833-470-1428 (domestic) and 404-975-4839 (international) with Access Code 459214. Investors can pre-register at https://events.q4inc.com/attendee/334189282. An audio webcast will be available after the call under Financials & Filings in the Investors section at www.iterumtx.com.
Positive
- None.
Negative
- None.
News Market Reaction 5 Alerts
On the day this news was published, ITRM gained 3.79%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $30M at that time.
Data tracked by StockTitan Argus on the day of publication.
DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 459214. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/334189282. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will Iterum Therapeutics (ITRM) report Q3 2025 financial results?
What time is Iterum Therapeutics' Q3 2025 earnings call and how can I join?
How can I pre-register for Iterum Therapeutics' November 14, 2025 conference call?
Will Iterum Therapeutics provide a webcast of the Q3 2025 call and where is it posted?
What will Iterum Discuss on the November 14, 2025 call for ITRM shareholders?
